Apr 10, 2022
20 years in, Genentech persists and perseveres in Alzheimer’s with gantenerumab
Posted by Kelvin Dafiaghor in categories: biotech/medical, health, neuroscience
Genentech’s Gregory Rippon, M.D., associates a few different phrases with the challenging nature of Alzheimer’s disease drug development: “cautious optimism,” “steady progress,” “an exercise in per | Genentech has been working on gantenerumab for 20 years, and, while it’s tempting to try to rush the clinical process, the Roche unit is slowly but surely following the evidence.